T Cell

T-cells are a critical component of the adaptive immune system and are indispensable in protecting humans from pathogenic infections.

Adoptive T Cell Therapy Methodology

Adoptive T cell therapy is a type of immunotherapy that has the ability to target cancer cells through inherent mechanisms of the immune system.

T-Cell Metabolism, Immunodeficiency and Human Disease

CAR-T Cell Toxicity and Safety Profiles

Adoptive T Cell Therapy Applications

New nanoparticle therapy overcomes T cell exhaustion in solid tumors

Engineers at the University of Pennsylvania have developed a new type of lipid nanoparticle (LNP) that could one day serve as a universal immunotherapy for cancers that form solid tumors, including common variants such as cancers of the breast, liver and colon.

18 Mar 2026

New CAR-T cell therapy shows promise for treating osteosarcoma

Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has puzzled medical researchers for 40 years.

17 Mar 2026

Simplified nanoparticles "educate" the immune system to find and destroy disease-causing cells

Johns Hopkins Medicine scientists say they have developed a simplified version of biodegradable nanoparticles that can "educate" the immune system to find and destroy disease-causing cells throughout the body.

11 Mar 2026

Microbial ecosystems influence success of cancer checkpoint immunotherapy

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies.

9 Mar 2026

Protein aggregates in the liver may protect against alcohol-induced damage

Alcohol-associated liver disease (ALD) remains a leading cause of cirrhosis and liver-related mortality worldwide, with few effective therapies.

9 Mar 2026

Combination therapy may help overcome barrier in early-stage prostate cancer treatment

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment.

26 Feb 2026

Next-generation CAR T therapy offers hope but faces clinical challenges

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment."

25 Feb 2026

Study identifies antiviral protein IFN-γ as a potential biomarker for Long COVID fatigue

SARS-CoV-2 triggers the production of the antiviral protein IFN-γ, which is associated with fatigue, muscle ache and depression.

23 Feb 2026

Distinct gut toxicity patterns emerge with targeted cancer treatments

A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled "Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection."

20 Feb 2026

Cornell study finds existing drug could boost liver cancer immunotherapy

Immunotherapy – which activates the body's own immune system to kill cancer cells – has not worked well against a rare and fatal liver cancer, but a new Cornell University study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment.

17 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Optimization of CAR T cells to destroy solid tumors

A team led by LMU physician Sebastian Kobold has found a way to allow the body's immune system to destroy solid tumors.

16 Feb 2026

Nanovaccine design boosts immune attack on HPV tumors

Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure.

11 Feb 2026

Alzheimer’s plaques decline after CAR-T immune cell treatment in preclinical study

Researchers engineered CD4+ chimeric antigen receptor T cells targeting fibrillar amyloid beta and tested them in a mouse Alzheimer model. The preclinical study showed reduced amyloid pathology and altered neuroimmune responses, supporting CAR-T immunotherapy as a potential future Alzheimer strategy.

11 Feb 2026

FDA label update expands CAR T access for primary CNS lymphoma

Dana-Farber Cancer Institute-led research helped drive an FDA label update for axicabtagene ciloleucel (Yescarta) that removes a prior exclusion for patients with primary central nervous system lymphoma, a rare and aggressive lymphoma of the brain and spinal cord.

9 Feb 2026

Artificial lung keeps patient alive after lung removal

Researchers evaluate the effectiveness of a novel extracorporeal total artificial lung system to enable bilateral pneumonectomy in patients with severe ARDS.

5 Feb 2026

Dual-responsive nanodelivery system enhances immunotherapy efficacy in metastatic bladder cancer

Metastatic urothelial carcinoma has a poor prognosis: ~50% of muscle-invasive bladder cancer progresses to metastasis, and the 5-year survival for advanced/metastatic disease is <10%.

24 Jan 2026

Chemotherapy-induced gut changes trigger anti-metastatic immune response

Chemotherapy commonly damages the intestinal lining, a well-known side effect. But this injury does not remain confined to the gut.

22 Jan 2026

Web-based cytometry atlas reveals immune signatures across pancreatic cancer treatments

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of vaccines and immune checkpoint inhibitor drugs, but it's not always clear which therapy is inducing what type of response.

16 Jan 2026

Aston Sci. Inc. implements CDD Vault to support AI-driven cancer vaccine development

Aston Sci. Inc., a clinical-stage biopharmaceutical company pioneering next-generation therapeutic cancer vaccines, announced today that it has implemented CDD Vault®, the secure, cloud-based research informatics platform from Collaborative Drug Discovery (CDD).

From CDD Vault 10 Jan 2026